Prostate Cancer Immunotherapy

Changing the outlook for metastatic prostate cancer

As the second most common male cancer in the world, roughly 1.3 million people receive a prostate cancer diagnosis each year. In its early stages, prostate cancer is highly treatable, but when advanced, effective treatments are limited. That’s where cancer immunotherapy offers new hope. There are already two FDA-approved immunotherapies—a therapeutic cancer vaccine and a checkpoint inhibitor—and many more promising treatments in clinical trials. Join Dr. Lawrence Fong of the UCSF Helen Diller Family Comprehensive Cancer Center to discuss exciting scientific and clinical research. She’ll answer your questions about biomarkers and genomic sequencing, combination therapies, clinical trials, side effects, and more.

Intro to CRI

Cancer Immunotherapy Basics: Harnessing Our Immune System to Fight Cancer

Clinical Trials and Cancer Immunotherapy: Accessing Promising Treatments

Patient Perspectives: Immunotherapy and Clinical Trial Experiences

Bladder Cancer Immunotherapy

Gynecologic Cancer Immunotherapy

Liver Cancer Immunotherapy

Skin Cancer and Melanoma Immunotherapy

Understanding and Overcoming Barriers to Accessing Cancer Care

Blood Cancer Immunotherapy

Breast Cancer Immunotherapy

Colorectal Cancer Immunotherapy

Kidney Cancer Immunotherapy

Lung Cancer Immunotherapy

Pancreatic Cancer Immunotherapy

Go back to event page

Hosts

Tamron Hall

Tamron Hall

Award-Winning TV Host, Journalist, Executive Producer, and Philanthropist

CRI Experts

Julie Brahmer, MD

Julie Brahmer, MD

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Andrea Cercek, MD

Andrea Cercek, MD

Memorial Sloan Kettering Cancer Center

Luis Diaz Jr., MD

Luis Diaz Jr., MD

Memorial Sloan Kettering Cancer Center

Peter E. Fecci, MD, PhD

Peter E. Fecci, MD, PhD

Duke Cancer Center, DukeHealth, and Duke University

Peter E. Fecci, MD, PhD

Lawrence Fong, MD

UCSF Helen Diller Family Comprehensive Cancer Center

Matthew D. Galsky, MD

Matthew D. Galsky, MD

The Tisch Cancer Institute

Sangeeta Goswami, MD, PhD

Sangeeta Goswami, MD, PhD

The University of Texas MD Anderson Cancer Center

Elizabeth Ann Mittendorf, MD, PhD

Elizabeth Ann Mittendorf, MD, PhD

Dana-Farber/Harvard Cancer Center

Kunle Odunsi, MD, PhD

Kunle Odunsi, MD, PhD

University of Chicago Medicine Comprehensive Cancer Center

Joseph E. Ravenell, MD

Joseph E. Ravenell, MD

Perlmutter Cancer Center NYU Langone Health

Marcel van den Brink, MD, PhD

Marcel van den Brink, MD, PhD

Memorial Sloan Kettering Cancer Center

Ana I. Velázquez Mañana, MD MSc

Ana I. Velázquez Mañana, MD MSc

UCSF Helen Diller Family Comprehensive Cancer Center

Robert H. Vonderheide, MD, DPhil

Robert H. Vonderheide, MD, DPhil

University of Pennsylvania Health System

Jennifer Wargo, MD, MMSc

Jennifer Wargo, MD, MMSc

The University of Texas MD Anderson Cancer Center

Jeffrey S. Weber, MD, PhD

Jeffrey S. Weber, MD, PhD

Perlmutter Cancer Center NYU Langone Health

Theodore H. Welling, MD

Theodore H. Welling, MD

Perlmutter Cancer Center NYU Langone Health

CRI ImmunoAdvocates

LaToya Bolds Johnson

LaToya Bolds-Johnson, PA-C, CAQ-EM

Breast Cancer Advocate & Thriver

Stephen Estrada

Stephen Estrada

Long-term Survivor of Stage 4 Colorectal Cancer

Stephanie Gangi

Stephanie Gangi

Breast Cancer Navigator

Sunshine Pegues

Sunshine Pegues

Lung Cancer Veteran

John White

John White

Prostate Cancer Veteran

CRI Moderators

Brian M. Brewer

Brian Brewer

Cancer Research Institute

Sponsors

Gold

Bristol Myers Squibb logo

Silver

Merck Logo

Contributor

AstraZeneca Logo
Genmab logo
Regeneron Logo

Friend

Lilly Oncology

Host Institutions

U Chicago Medicine Comprehensive Cancer Center Logo
Dana Farber Cancer Institute Logo
MD Anderson Cancer Center Logo

Request a clinical trials orientation appointment

Questions?

This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.